Ozanimod

• Description:

  Ozanimod (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5) . Ozanimod has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) [1].

• Product Name Alternative:

  RPC-1063

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  LPL Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Ozanimod.html

• Concentration:

  10mM

• Purity:

  99.98

• Solubility:

  DMSO : ≥ 29 mg/mL

• Smiles:

  N#CC1=CC(C2=NC(C3=CC=CC4=C3CC[C@@H]4NCCO)=NO2)=CC=C1OC(C)C

• Molecular Formula:

  C23H24N4O3

• Molecular Weight:

  404.46

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Julie V Selkirk, et al. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5. J Pharmacol Exp Ther. 2021 Dec;379 (3) :386-399.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  S1PR1; S1PR5

• CAS Number:

  [1306760-87-1]